Skip to main content

Table 6 Expected Value of Perfect Information for Parameters

From: Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis

Parameter Population EVPPI ($) Population EVPI ($)
Low Risk   27,076,912
Relative Risk of Thiazide   
Stroke -  
CHD -  
Death -  
Utility   
Non-symptomatic 5,576  
Stroke 2,938  
CHD 5,006  
Cost   
Stroke Hospitalization 16,518  
CHD Hospitalization 14,984  
Stroke Manage -  
Yearly Cost Thiazide 178  
Moderate Risk   73,353,965
Relative Risk of Thiazide   
Stroke 3,093,981  
CHD 2,648,842  
Death 7,221,002  
Utility   
Non-symptomatic 2,092,005  
Stroke 3,003,524  
CHD 2,303,848  
Cost   
Stroke Hospitalization 1,224,642  
CHD Hospitalization 1,781,143  
Stroke Manage 2,392,084  
Yearly Cost Thiazide 4,126,641  
High Risk   26,667,500
Relative Risk of Thiazide   
Stroke 9,901,387  
CHD 5,441,116  
Death 646,992  
Utility   
Non-symptomatic 1,137,622  
Stroke 2,005,656  
CHD 1,336,286  
Cost   
Stroke Hospitalization 1,378,708  
CHD Hospitalization 2,908,565  
Stroke Manage 660,668  
Yearly Cost Thiazide 437,657